The impact of thyroid disorder on cardiovascular disease: Unraveling the connection and implications for patient care - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39507294/
The thyroid gland is responsible for metabolism, as well as cardiac function and the peripheral vascular system. Thyroid dysfunctions are associated with an increase in the risk of cardiovascular diseases,...
Thyroid dysfunctions increase cardiovascular disease risks, including heart failure, atrial fibrillation, and stroke. Amiodarone use can induce thyroid issues, requiring monitoring. Screening and treatment are essential for CVD patients' health outcomes.
Share
Management of dyslipidemia in special groups - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38336098/
Dyslipidemia management in situations like pregnancy, in diseases like rheumatoid arthritis, human immunodeficiency virus (HIV) disease, chronic liver disease, and in the elderly are challenging scenarios. Pregnancy is a contraindication...
This manuscript discusses the challenges of managing dyslipidemia in pregnancy, rheumatoid arthritis, HIV, chronic liver disease, elderly patients, and COVID-19, highlighting unique treatment considerations and limited available data.
Share
Weight Loss and Glycemic Control After Bariatric Surgery in Adolescents With Severe Obesity: A Randomized Controlled Trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38069930/
Bariatric surgery was associated with substantial weight loss and improvements in glucose and lipid metabolism after 12 months compared to conservative treatment in adolescents with severe obesity.
Bariatric surgery led to significant weight loss and metabolic improvements in adolescents with severe obesity after failed lifestyle intervention, outperforming conservative treatment in a one-year randomized trial.
Share
Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38679221/
Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated clinically important weight loss effects in patients with type 2 diabetes. However, its effects on sustained weight loss in patients without diabetes...
Semaglutide (2.4 mg) significantly reduces body weight in overweight/obese individuals without diabetes, with a 12.1% relative weight loss. Gastrointestinal adverse events are common but mostly mild. Long-term efficacy and safety are confirmed.
Share
Targeting the GDF15 Signalling for Obesity Treatment: Recent Advances and Emerging Challenges - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39700016/
The growth differentiation factor 15 (GDF15)-glial cell-derived neurotrophic factor family receptor alpha-like (GFRAL) pathway plays a crucial role in the regulation of metabolism, appetite and body weight control. Obesity is...
The GDF15-GFRAL pathway regulates metabolism, appetite, and obesity. Targeting this axis offers a promising strategy for obesity treatment, with minimal impact on muscle mass, though challenges remain in its application.
Share